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Rapid diagnosis of pulmonary tuberculosis in African 
children in a primary care setting by use of Xpert MTB/RIF on 
respiratory specimens: a prospective study
Heather J Zar, Lesley Workman, Washiefa Isaacs, Keertan Dheda, Widaad Zemanay, Mark P Nicol
Summary
Background In children admitted to hospital, rapid, accurate diagnosis of pulmonary tuberculosis with the Xpert 
MTB/RIF assay is possible, but no paediatric studies have been done in the primary care setting, where most children 
are given care, and where microbiological diagnosis is rarely available. We assessed the diagnostic accuracy of Xpert 
MTB/RIF in children in primary care.
Methods For this prospective study, we obtained repeat induced sputum and nasopharyngeal aspirate specimens from 
children (<15 years) with suspected pulmonary tuberculosis at a clinic in Khayeliwtsha, Cape Town, South Africa. We 
compared the diagnostic accuracy of Xpert MTB/RIF with a reference standard of culture and smear microscopy on 
induced sputum specimens. For the main analysis, speciﬁ city of Xpert MTB/RIF versus liquid culture, we included only 
children with two interpretable Xpert MTB/RIF and induced sputum culture results. 
Findings Between Aug 1, 2010, and July 30, 2012, we enrolled 384 children (median age 38·3 months, 
IQR 21·2–56·5) who had one paired induced sputum and nasopharyngeal specimen, 309 (81%) of whom had two 
paired specimens. Five children (1%) tested positive for tuberculosis by smear microscopy, 26 (7%) tested positive by 
Xpert MTB/RIF, and 30 (8%) tested positive by culture. Xpert MTB/RIF on two induced sputum specimens 
detected 16 of 28 culture-conﬁ rmed cases (sensitivity of 57·1%, 95% CI  39·1–73·5) and on two nasopharyngeal 
aspirates detected 11 of 28 culture-conﬁ rmed cases (sensitivity of 39·3, 23·6–57·6; p=0·18). The speciﬁ city of Xpert 
MTB/RIF on induced sputum was 98·9% (95% CI 96·9–99·6) and on nasopharyngeal aspirates was 99·3% 
(97·4–99·8). 
Interpretation Our ﬁ ndings suggest that Xpert MTB/RIF on respiratory secretions is a useful test for rapid diagnosis 
of paediatric pulmonary tuberculosis in primary care.
Funding National Institutes of Health, National Health Laboratory Services Research Trust, the Medical Research 
Council of South Africa, the National Research Foundation South Africa, the European and Developing Countries 
Clinical Trials Partnership.
Introduction
Diagnosis of pulmonary tuberculosis in children can be 
challenging because of non-speciﬁ c symptoms, signs, 
and radiological features.1 Diagnostic uncertainty is 
compounded by HIV co-infection because tuberculosis 
can be diﬃ  cult to distinguish from other HIV-associated 
diseases. Missed diagnosis of paediatric pulmonary 
tuberculosis is an important problem, with up to 40% of 
children admitted to hospital with culture-conﬁ rmed 
tuberculosis being discharged without appropriate 
treatment because culture conﬁ rmation can take 
several weeks.2–4 In the community setting, the proportion 
of missed cases can be even higher because many 
patients have less severe disease presentation. Rapid 
microbiological conﬁ rmation of tuberculosis and 
identiﬁ cation of drug resistance is therefore desirable 
because it enables deﬁ nitive diagnosis and initiation of 
appropriate treatment.5
The Xpert MTB/RIF assay (Xpert; Cepheid, CA, USA) 
has enabled rapid diagnosis of pulmonary tuberculosis 
and detection of resistance to rifampicin in children 
admitted to hospital. We previously reported that Xpert 
MTB/RIF on two induced sputum specimens correctly 
identiﬁ ed 44 (76%) of 58 children in hospital with culture-
conﬁ rmed disease.6 Similar results have been reported in 
hospital-based studies of children with suspected 
tuberculosis in Uganda and Tanzania using sputum or 
induced sputum specimens.7,8 Findings from a Zambian 
study showed that Xpert MTB/RIF done on gastric lavage 
specimens in children admitted to hospital had a 
sensitivity of 65%, whereas in older children the sensitivity 
on spontaneously produced sputum was 90%.9 We also 
reported that Xpert MTB/RIF on two nasopharyngeal 
aspirates was useful for microbiological conﬁ rmation in 
children in hospital.10 Although nasopharyngeal aspirates 
provided a lower culture yield than induced sputum, the 
sensitivity of two Xpert MTB/RIF tests on nasopharyngeal 
aspirates was similar to Xpert MTB/RIF on two induced 
sputum specimens, 71% on induced sputum and 65% on 
nasopharyngeal aspirate specimens.10
Most children with suspected pulmonary tuberculosis 
present to primary clinics, but microbiological diagnosis 
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is rarely attempted because of limited capacity and the 
perception that microbiological diagnosis is neither 
feasible nor useful in children in primary care. 
Nevertheless, microbiological investigations might enable 
deﬁ nitive diagnosis and improve treatment in primary 
care, as shown by ﬁ ndings from a South African study in 
which culture and smear on induced sputum increased 
diagnostic yield by 22% in a paediatric clinic.11 Xpert MTB/
RIF could oﬀ er a feasible option for rapid microbiological 
diagnosis and detection of rifampicin resistance in 
children in primary care. More over, nasopharyngeal 
aspirates are an attractive option for use in primary care, 
where lack of capacity to collect induced sputum 
specimens has been an obstacle to eﬀ ective microbiological 
diagnosis and where gastric lavage can be diﬃ  cult as an 
ambulatory procedure. We know of no studies that 
describe the accuracy of Xpert MTB/RIF in children 
recruited exclusively from a primary care clinic. We 
therefore prospectively assessed the accuracy of Xpert 
MTB/RIF on induced sputum and nasopharyngeal 
aspirate specimens using culture of induced sputum as a 
reference standard for diagnosis of pulmonary 
tuberculosis in children at a primary care clinic.
Methods
Study design and participants
For this prospective study, we recruited participants from 
Nolungile primary care clinic in Khayelitsha, Cape Town, 
South Africa, an area in which the incidence of tuberculosis 
is high. We enrolled consecutive children presenting from 
Aug 1, 2010, to July 30, 2012, with suspected pulmonary 
tuberculosis. Children younger than 15 years were eligible 
if they had a cough for more than 14 days and one of the 
following: a household tuberculosis contact within the 
previous 3 months, weight loss or failure to gain weight 
within the previous 3 months, a positive skin test to 
puriﬁ ed protein derivative (PPD 2TU, PPD RT23; Staten 
Serum Institute, Copenhagen, Denmark), or a chest 
radiograph suggestive of pulmonary tuberculosis. A 
positive skin test was deﬁ ned as 5 mm or more of 
transverse induration in children with HIV or 10 mm or 
more in children without HIV. We excluded children for 
the following reasons: if they had received tuberculosis 
treatment or prophylaxis within the previous 72 h, if they 
could not be followed up, if informed consent was 
unobtainable, or if an induced sputum and nasopharyngeal 
aspirate specimen could not be obtained.
A history and physical examination were done at 
enrolment. Clinical investigations included chest 
radiography, skin test, and HIV testing in children 
whose HIV status was unknown (HIV rapid test, 
followed by a conﬁ rmatory PCR for children younger 
than 18 months or HIV ELISA in older children). HIV-
infected children were classiﬁ ed by WHO clinical 
staging; CD4 count and HIV viral load were recorded 
and children were classiﬁ ed by the CDC immunological 
classiﬁ cation. Two independent reviewers, masked to 
microbiological and other results, reported chest 
radiographs using a standardised format. Signs 
suggestive of tuberculosis included airway compression 
or lymphadenopathy, diﬀ use miliary pattern, pleural 
eﬀ usion, or cavitary disease.
Tuberculosis treatment was given at the discretion of 
the treating clinician on the basis of clinical, radiological, 
and microbiological information. Xpert MTB/RIF results 
were communicated to the clinic doctor as soon as they 
were available. Follow-up visits were done at months 1, 3, 
and 6 for children on tuberculosis treatment and 
at months 1 and 3 for those untreated. Response to 
treatment was assessed at follow-up by recording 
symptoms, signs, weight, and a repeat chest radiograph 
at completion of treatment.
Written, informed consent was obtained from a parent 
or legal guardian. The study was approved by the 
Figure: Study proﬁ le
IS=induced sputum. NPA=nasopharyngeal aspirate. 
600 children screened
415 children enrolled
185 children excluded
 175 not eligible
 10 refused to consent 
384 children with one IS and NPA specimen
309 children with two IS and NPA specimens
30 (8%) definite tuberculosis 
 30 (100%) IS culture-positive 
 17 (57%) IS Xpert MTB/RIF-positive
 12 (40%) NPA Xpert MTB/RIF-positive
 19 (63%) IS or NPA Xpert MTB/RIF-positive
 4 (13%) smear-positive
167 (44%) possible tuberculosis 
 0 IS culture-positive 
 5 (2%) IS Xpert MTB/RIF-positive
 5 (2%) NPA Xpert MTB/RIF-positive
 7 (4%) IS or NPA Xpert MTB/RIF-positive
 1 (<0·5%) smear-positive
187 (49%) not tuberculosis 
 0 IS culture-positive 
 0 IS Xpert MTB/RIF-positive
 0 NPA Xpert MTB/RIF-positive
 0 IS or NPA Xpert MTB/RIF-positive
 0 smear-positive
31 excluded (without a valid IS culture or
NPA Xpert MTB/RIF result)
25 IS contaminated non-tuberculosis
      mycobacterium 
1 IS culture not done 
4 NPA Xpert MTB/RIF not done 
1 NPA indeterminate
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Research Ethics Committee, Faculty of Health Sciences, 
University of Cape Town, and the Provincial Research 
Ethics Committee of the Western Cape.
Respiratory specimens
We took two paired induced sputum and nasopharyngeal 
aspirate specimens at baseline (four specimens in total) 
and submitted them individually to a central laboratory 
for Xpert MTB/RIF testing. The induced sputum 
specimens were also submitted individually for smear 
and liquid culture because the yield from culture from 
induced sputum has been shown to be substantially 
higher than that from nasopharyngeal aspirates.10
A nasopharyngeal aspirate was obtained before induced 
sputum as described elsewhere.10 Two drops of sterile 
saline were instilled into each of the patients’ nostrils and 
the nasopharynx was suctioned with a sterile catheter 
with a mucus trap. A second nasopharyngeal aspirate 
was obtained the following day or a minimum of 4 h after 
the ﬁ rst induced sputum procedure.
Sputum induction was done by a trained research 
nurse at least 30 min after a nasopharyngeal aspirate was 
obtained, following a 2–3 h fast in a dedicated room, as 
described elsewhere.11,12 A second induced sputum 
specimen was obtained, whenever possible, the following 
day or a minimum of 4 h after the ﬁ rst specimen. We did 
baseline arterial pulse oximetry and monitoring during 
the induced sputum procedure and for 30 min thereafter. 
Caregivers were reimbursed for transport costs for a 
second visit, when the second paired induced sputum 
and nasopharyngeal aspirate specimens were taken the 
following day.
Laboratory assays
Nasopharyngeal aspirate and induced sputum specimens 
were transported within 2 h of collection to an accredited 
centralised laboratory and processed individually using 
standardised protocols by trained laboratory technicians. 
For both specimens, after decontamination with N-acetyl-
L-cysteine and sodium hydroxide (1% ﬁ nal concentration), 
centrifuged deposits were resuspended in 1·5 mL of 
phosphate buﬀ er. A drop of induced sputum sediment 
was used for ﬂ uorescent acid-fast smear microscopy. For 
Xpert MTB/RIF, 1·4 mL of specimen reagent was added 
to 0·7 mL of resuspended sputum or nasopharyngeal 
aspirate pellet and processed as reported elswhere.6 
Automated liquid culture (BACTEC MGIT; Becton 
Dickinson, MD, USA) was done using 0·5 mL of 
resuspended pellet on sputum specimens. Cultures were 
incubated for up to 6 weeks. Positive cultures were 
identiﬁ ed by acid-fast staining followed by MTBDRplus 
testing (Hain Lifesciences, Hehren, Germany) to conﬁ rm 
the presence of Mycobacterium tuberculosis and rifampicin 
and isoniazid resistance.13 Because culture results were 
Overall (N=384) Deﬁ nite 
tuberculosis 
(N=30)
Possible 
tuberculosis 
(N=167)
Not tuberculosis 
(N=187)
Odds ratio (95% CI)
Age in months (median [IQR]) 38·3 (21·2 to 56·5) 39·8 (26·8 to 56·5) 37·2 (22·0 to 55·0) 40·1 (19·8 to 59·4) 1·00 (0·99 to 1·02)
Sex (male) 181 (47%) 17 (57%) 81 (41%) 83 (45%) 1·5 (0·71 to 3·21)
HIV infection 31 (8%) 5 (16%) 14 (8%) 12 (6%) 2·5 (0·9 to 7·1)
WHO HIV clinical staging 4·86 (1·62 to 14·58)
Stage 1 11 (36%) 0 0 11 (92%) ··
Stage 2 1 (3%) 0 1 (7%) 0 ··
Stage 3 19 (61%) 5 (100%) 13 (93%) 1 (8%) ··
Stage 4 0 0 0 0 ··
HIV CDC immune category 4·03 (0·41 to 40·03)
Mild 13 (46%) 4 (67%) 5 (42%) 4 (40%) ··
Moderate 11 (40%) 1 (17%) 4 (33%) 6 (60%) ··
Severe 4 (14%) 1 (17%) 3 (25%) 0 ··
History of tuberculosis 42 (11%) 3 (9%) 15 (9%) 24 (13%) 0·94 (0·13 to 2·48)
Radiological changes suggestive of tuberculosis* 314 (82%) 26 (87%) 145 (87%) 143 (77%) 1·49 (0·50 to 4·41)
Started on tuberculosis treatment 180 (47%) 28 (93%) 152 (91%) 0 17·5 (4·10 to 74·63)
Z scores (median [IQR])
HAZ –0·8 (–1·7 to 0·1) –0·3 (–1·1 to 0·4) –0·8 (–1·7 to 0·1) –0·9 (–1·7 to 0·1) 1·39 (1·03 to 1·87)
WAZ –0·5 (–1·3 to 0·4) 0·0 (–1·2 to 0·9) –0·7 (–1·6 to 0·3) –0·4 (–1·3 to 0·3) 1·28 (0·99 to 1·64)
WHZ 0·2 (–0·9 to 1·1) 0·3 (–0·6 to 1·9) 0·1 (–1·2 to 0·8) 0·3 (–0·5 to 1·2) 1·12 (0·87 to 1·46)
Malnutrition† (a WAZ score less than –2) 50 (13%) 5 (13%) 25 (15%) 21 (11%) 0·94 (0·31 to 2·79)
Tuberculin skin positive‡ 259 (69%) 28 (83%) 121 (73%) 113 (63%) 2·39 (0·89 to 6·42)
Data are median n (%) unless otherwise stated. CDC=US Centers for Disease Control and Prevention. HAZ=height for age Z score. WAZ=weight for age Z score. WHZ=weight 
for height Z score. *n=304. †n=370. ‡n=376.
Table 1: Baseline characteristics
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not available at the time of Xpert MTB/RIF testing, staﬀ  
doing and recording Xpert MTB/RIF tests were masked 
to culture results. If Xpert MTB/RIF identiﬁ ed rifampicin 
resistance, the corresponding cultured isolate also 
underwent phenotypic resistance testing by automated 
liquid MGIT culture.
Statistical analysis
We assigned children to one of three categories on the 
basis of clinical and microbiological investigations: 
deﬁ nite tuberculosis (any induced sputum culture 
positive for M tuberculosis), not tuberculosis (culture-
negative and documented resolution of symptoms and 
signs at a follow-up visit at 3 months  in children who did 
not receive tuberculosis treatment), or possible 
tuberculosis (all other children).
The primary reference standard was a positive culture 
for M tuberculosis on induced sputum. We analysed 
separately patients with at least one paired induced sputum 
and nasopharyngeal aspirate specimens from those with 
two paired specimens. For the primary analysis of the 
speciﬁ city of Xpert MTB/RIF we included only children 
with two interpretable Xpert MTB/RIF and induced 
sputum culture results, because a single negative culture 
result is likely to miss a substantial proportion of culture-
conﬁ rmed cases. We calculated the sensitivity, speciﬁ city, 
and predictive values of the assays with 95% CIs. We used 
simple descriptive statistics to characterise the study 
population and summarised normally distributed 
continuous data as means with 95% CIs and non-normally 
distributed continuous data as medians with IQRs. We 
summarised categorical data as proportions with 95% CIs. 
Statistical tests included two-group test of proportions, 
univariate logistic regression, and Wilcoxon rank-sum test. 
Statistical tests were two-sided with an α of 0·05.
We used EpiInfo (version 6) for calculation of 
nutritional indices and STATA (version 10) for all other 
statistical analyses.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
We enrolled 415 children, 384 (93%) of whom had at least 
one induced sputum specimen and one nasopharyngeal 
aspirate (ﬁ gure). Table 1 shows characteristics of 
participants at baseline. Although few children had 
severe malnutrition, many had mild nutritional 
impairment (table 1). 22 (71%) of the 31 children with 
HIV were on highly active antiretroviral therapy 
(HAART).
Of the 384 children with at least one induced sputum 
and nasopharyngeal aspirate specimen, ﬁ ve (1%) had a 
positive smear, 26 (7%) had a positive Xpert MTB/RIF, 
and 30 (8%) had a positive culture result (ﬁ gure). There were 
30 (8%) children with deﬁ nite tuberculosis, 167 (44%) 
with possible tuberculosis, and 187 (49%) without 
tuberculosis. Excluding children classiﬁ ed as not having 
tuberculosis, 30 (15%) of 197 children had culture-
conﬁ rmed diseases, of whom 19 (63%) were Xpert-MTB/
RIF-positive on a respiratory specimen. 180 children 
were started on tuberculosis treatment, representing 47% 
of the total sample and 91% of those with deﬁ nite or 
possible tuberculosis. The median time from 
presentation at clinic to treatment initiation was 2 days 
(IQR 0–9). In children with deﬁ nite tuberculosis, ﬁ ve 
(16%) were HIV-positive and 25 (7%) were HIV-negative 
(odds ratio 2·5, 95% CI 0·86–7·14). 19 HIV-positive 
Sensitivity Speciﬁ city PPV NPV
Xpert MTB/RIF (induced sputum) 13/30; 43·3% (27·4–60·8) 351/354; 99·2% (97·5–99·7) 81·3 95·4
Xpert MTB/RIF (nasopharyngeal aspirate) 9/30; 30·0% (16·7–47·9) 350/354; 98·9% (97·1–99·6) 69·2 94·3
Xpert MTB/RIF (induced sputum or nasopharyngeal aspirate) 19/30; 63·3% (45·5–78·1) 347/354; 98·0% (96·0–99·0) 73·1 96·9
Smear microscopy (induced sputum) 4/30; 13·3% (5·3–29·7) 353/354; 99·7% (98·4–100·0) 80·0 93·1
Data are n/N; % (95% CI), unless otherwise stated. PPV=positive predictive value. NPV=negative predictive value. 
Table 2: Accuracy of Xpert MTB/RIF compared with liquid culture on induced sputum in children with at least one sputum specimen and one 
nasopharyngeal aspirate specimen (N=384)
Sensitivity Speciﬁ city PPV NPV
Xpert MTB/RIF 
(ﬁ rst IS specimen)
12/28; 42·9% (26·5–60·9) 280/281; 99·6% (98·0–99·9) 92·3 94·6
Xpert MTB/RIF 
(both IS specimens)
16/28; 57·1% (39·1–73·5) 278/281; 98·9% (96·9–99·6) 84·2 95·9
Xpert MTB/RIF 
(ﬁ rst NPA specimen)
8/28; 28·6% (15·3–47·1) 280/281; 99·6% (98·0–99·9) 88·9 93·3
Xpert MTB/RIF 
(both NPA specimens)
11/28; 39·3% (23·6–57·6) 279/281; 99·3% (97·4–99·8) 84·6 94·3
Xpert MTB/RIF 
(ﬁ rst IS or NPA specimen)
14/28; 50·0% (32·6–67·4) 279/281; 99·3% (97·4–99·8) 87·5 95·2
Xpert MTB/RIF 
(both IS or NPA specimens)
18/28; 64·3% (45·8–79·3) 277/281; 98·6% (96·4–99·4) 81·8 96·5
Smear microscopy 3/28; 10·7% (3·7–27·2) 280/281; 99·6% (98·0–99·9) 75·0 99·6
Data are n/N; % (95% CI) unless otherwise stated.IS=induced sputum. NPA=nasopharyngeal aspirate. PPV=positive 
predictive value. NPV=negative predictive value 
Table 3: Accuracy of Xpert MTB/RIF and smear compared with liquid culture in children with two paired 
induced sputum and nasopharyngeal aspirate specimens (N=309)
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children (61%) and 161 (46%) HIV-negative children were 
started on tuberculosis treatment (p=0·09). No child was 
admitted to hospital.
19 of 30 (63%) children with deﬁ nite tuberculosis had 
at least one positive MTB/RIF on induced sputum or 
nasopharyngeal aspirate, as did seven of 167 (4%) 
children with possible tuberculosis and none 
of 187 children without tuberculosis (ﬁ gure). 
Table 2 shows the accuracy of Xpert MTB/RIF on 
respiratory specimens in children with at least one paired 
induced sputum and nasopharyngeal aspirate. In children 
with deﬁ nite tuberculosis, there was at least one positive 
Xpert MTB/RIF result in 13 (43%) of 30 induced sputum 
specimens and in nine (30%) of 30 nasopharyngeal 
aspirates. In those with possible tuberculosis, a positive 
Xpert MTB/RIF occurred in three (2%) of 167 induced 
sputum specimens and in four (2%) of 167 nasopharyngeal 
specimens. We recorded no positive Xpert MTB/RIF in 
the not tuberculosis group. The sensitivity of smear on 
induced sputum specimens (four of 30 specimens; 13%, 
95% CI 5–30) was lower than Xpert MTB/RIF (19 of 30 
specimens; 63%, 46–78; p<0·0001). Xpert MTB/RIF on 
respiratory specimens detected all four smear-positive 
cases (100%, 51–100) and 15 of 26 smear-negative cases 
(58%, 39–75). The median time from taking respiratory 
specimens to communicating an Xpert MTB/RIF result to 
staﬀ  at the primary care site was 1 day. This was possible 
due to the eﬃ  cient transfer of specimens to the laboratory, 
real-time performance of Xpert MTB/RIF, and electronic 
communication between the lab and study staﬀ  at the site.
309 children (81%) had a valid second induced sputum 
and nasopharyngeal aspirate specimen, 28 (9%) of whom 
had culture-conﬁ rmed disease. Two paired induced 
sputum and nasopharyngeal aspirate specimens were 
obtained on the same day in 148 (48%) of the 
309 children, while the rest had a second paired specimen 
the following day. A single Xpert MTB/RIF test on 
induced sputum or nasopharyngeal aspirate detected 
half of cases (table 3), including all three smear-positive 
cases (100%, 44–100) and 11 of 25 smear-negative cases 
(44%, 27–63). The sensitivity of two Xpert MTB/RIF tests 
on induced sputum specimens (16 of 28; 57%, 39–75) 
was higher but not signiﬁ cantly diﬀ erent to that on two 
nasopharyngeal aspirates (11 of 28; 39%, 24–58; p=0·18; 
table 3). Xpert MTB/RIF was more than ﬁ ve times as 
sensitive as smear microscopy on induced sputum 
specimens (table 3).
A second induced sputum increased the detection rate 
for Xpert MTB/RIF by 33% (from 12 cases to 16 cases; 
table 3); the incremental yield of a second induced sputum 
culture was four cases (a 17% increase), from 24 cases 
to 28 cases (data not shown). A second nasopharyngeal 
aspirate increased the sensitivity of Xpert MTB/RIF by 
three cases (38%), from eight cases to 11 cases (table 3).
Seven children classiﬁ ed as having possible tuberculosis 
had a positive Xpert MTB/RIF and negative culture results 
(ﬁ gure). Three of these seven children had a single 
negative culture and four had two negative cultures; all 
were treated for pulmonary tuberculosis and had a good 
clinical response. 
When results for rifampicin susceptibility testing were 
available from culture (followed by MTBDRplus) and Xpert 
MTB/RIF, all were susceptible by Xpert MTB/RIF and 
MTBDRplus. On a per specimen analysis, the sensitivity 
and speciﬁ city of Xpert MTB/RIF for rifampicin resistance 
were each 100%. Xpert MTB/RIF provided faster results 
(time from obtaining specimen to reporting to clinician)
than culture (median 1 day [IQR 1–1] vs 16 days [13–19]; 
p=0·0001). The number of Xpert MTB/RIF tests recorded 
as failures or invalid (12 of 1754 [<0·5%]) was smaller than 
the number of cultures recorded as contaminated 
(58 of 1128 [1%]; p=0·0001).
Discussion
In this study, Xpert MTB/RIF on respiratory specimens 
detected within a day almost two-thirds of children with 
culture-conﬁ rmed tuberculosis who were not admitted to 
hospital. Xpert MTB/RIF was much more sensitive than 
smear microscopy, detecting almost ﬁ ve times the 
number of pulmonary tuberculosis cases. Furthermore, 
Xpert MTB/RIF was useful for diagnosis of tuberculosis 
in both HIV-infected and HIV-uninfected children. Xpert 
MTB/RIF identiﬁ ed an additional group of children in 
the possible-tuberculosis group who probably had 
tuberculosis based on clinical features and response to 
therapy but with negative cultures. Assuming that these 
were true positive cases, the overall yield of culture (30 
cases) and Xpert MTB/RIF (26 cases) in this cohort were 
similar. This ﬁ nding suggests that MTB/RIF can identify 
additional cases over culture in children with milder 
illness and paucibacillary disease.
This is the ﬁ rst paediatric study to show the usefulness 
of Xpert MTB/RIF in primary care settings, enabling 
timely treatment of children with appropriate drugs. Our 
ﬁ ndings also show the feasibility of obtaining respiratory 
specimens in primary care even in young children, as 
indicated by the high success rate for induced sputum 
and nasopharyngeal aspirate procedures. This ﬁ nding is 
consistent with our previous report in which induced 
sputum was successfully obtained in almost all children 
(269 of 270) with suspected pulmonary tuberculosis at 
another clinic.11
The culture positivity rate in this study was lower than 
those in previous hospital-based studies;6,10,12 but similar 
to that in a paediatric study of induced sputum at another 
tuberculosis clinic in the same area.11 Children presenting 
in primary care are less ill than  hospitalised populations, 
as indicated by the need for ambulatory treatment only, 
in all children in the present study. Also, unless Xpert 
MTB/RIF is done at the point of care, operational issues 
such as transport of specimens can be more challenging 
in primary care than they are in hospitals.
The sensitivity of Xpert MTB/RIF was also lower than 
that reported in studies of children admitted to hospital 
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in South Africa, Zambia, Uganda, and Tanzania, with 
sensitivities of 72–90% on sputum specimens.6–10 
Findings from a Zambian study showed a sensitivity 
of 90% on spontaneously produced sputum, but children 
were older than were those in the present study, and a 
higher proportion (51%) had HIV.9 In younger children, 
the sensitivity of Xpert MTB/RIF on gastric lavage was 
reported as 65%, which was similar to our ﬁ nding for 
tests done on induced sputum (57%).9 Findings from a 
hospital-based study of Ugandan children showed that 
Xpert MTB/RIF on induced sputum detected 79% of 
culture-conﬁ rmed cases.8 An age of greater than 5 years 
was independently associated with a positive Xpert MTB/
RIF; almost a third were older than 5 years, by contrast 
with the present study in which the median age 
was 38 months.
Children with less severe illness might have a lower 
bacillary load, further accounting for the lower 
sensitivity of Xpert MTB/RIF in ambulatory settings. 
This notion is lent support by the very small number of 
smear-positive cases in the present study, which was 
also lower than that seen in children admitted to 
hospital.6,10 The sensitivity of Xpert MTB/RIF was higher 
in smear-positive than it was in smear-negative cases, as 
has also been shown in children in hospital.6,7,10 Findings 
from a Cochrane review of Xpert MTB/RIF in adults 
with suspected tuberculosis showed a similar pooled 
sensitivity of 68% for smear-negative cases.14 Therefore, 
the sensitivity of Xpert MTB/RIF in this study, in which 
most children had negative smear microscopy results, is 
consistent with that reported in both adults and children 
with smear-negative disease.  Development of a more 
sensitive PCR diagnostic test than Xpert MTB/RIF, 
which has a limit of detection of 130 colony-forming 
units per mL,15 could be especially useful for the 
detection of less severe cases of pulmonary tuberculosis 
in children.
The sensitivity of Xpert MTB/RIF on induced sputum 
was higher but not signiﬁ cantly diﬀ erent to that on 
nasopharyngeal aspirates. This ﬁ nding is consistent 
with results from a study done in children in hospital,10 
in which culture yield was substantially higher from 
induced sputum and the yield from induced sputum 
Xpert MTB/RIF was higher but not signiﬁ cantly 
diﬀ erent from nasopharyngeal aspirates. These 
ﬁ ndings are lent support by paediatric studies done in 
Uganda, Yemen, and Peru, reporting nasopharyngeal 
aspirates to be useful for diagnosis using culture or in-
house PCR methods.16–19 The higher yield from Xpert 
MTB/RIF on induced sputum than on nasopharyngeal 
aspirates could, however, be clinically signiﬁ cant; 
further study with a larger sample size is needed to 
address this. Overall, our results suggest that induced 
sputum specimens are preferable to nasopharyngeal 
aspirate specimens. In a previous study at another 
tuberculosis clinic in this area, nursing staﬀ  rated 
induced sputum specimens as easy or very easy to 
obtain from most children.11 Induced sputum requires 
nebulisation with hypertonic saline and suctioning—
hypertonic saline nebulisation is now recommended 
for children with bronchiolitis,20 and suctioning is 
routinely done by nurses in primary care. Therefore, 
more widespread use of induced sputum should be 
considered in primary care. Infection control 
procedures such as use of protective masks should be 
implemented to prevent transmission. However, 
obtaining induced sputum specimens might not be 
possible in many primary care clinics in high-
tuberculosis, low-resource settings in view of the need 
for trained health-care workers, oxygen, and electricity 
to do this procedure. When induced sputum is 
unobtainable, nasopharyngeal aspirate samples remain 
useful for Xpert MTB/RIF, especially because they are 
easily obtained in primary care.
Consistent with ﬁ ndings from our previous studies,6,10,12 
the yield from both culture and Xpert MTB/RIF increased 
substantially with a second specimen. Therefore, two 
specimens (whether induced sputum or nasopharyngeal 
aspirate) should be recommended in children. These 
results are also consistent with a Tanzanian study that 
reported an incremental yield with repeated induced 
sputum in children whether culture, Xpert MTB/RIF, or 
a combination were used.7 Further study of the cost-
Panel: Research in context
Systematic review
When planning the study, we searched PubMed for articles 
published in English up to Dec 31, 2009, using the search 
terms “child”, “tuberculosis”, “diagnosis”, “Xpert”, and 
“MTB/RIF”. We identiﬁ ed no articles. For the writing of the 
paper, we repeated this search with an additional term 
“primary care” for articles published up until March 30, 2013. 
We identiﬁ ed ﬁ ve hospital-based studies of use of Xpert for 
diagnosis of childhood tuberculosis, but there were no 
studies done in a primary care setting.
Interpretation
This study provides the ﬁ rst evidence that Xpert MTB/RIF on 
respiratory specimens (induced sputum or nasopharyngeal 
aspirates) can be useful for rapid diagnosis of pulmonary 
tuberculosis in children in a primary care setting. Our ﬁ ndings 
show that the yield from culture or Xpert MTB/RIF was lower 
than that reported for children in hospital, suggesting a lower 
bacillary load associated with less severe illness. Consistent 
with hospital studies, repeated specimens for Xpert MTB/RIF 
resulted in a higher diagnostic yield. Xpert MTB/RIF was much 
more sensitive than was smear microscopy, and results were 
available faster than they were for culture. The previous 
evidence base suggested that Xpert MTB/RIF done on 
respiratory specimens is eﬀ ective for diagnosis of pulmonary 
tuberculosis in children admitted to hospital; this study 
suggests that use of Xpert MTB/RIF is also feasible and useful 
in primary care settings. 
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eﬀ ectiveness of repeated specimens is needed in 
children. However, ﬁ ndings from a cost-eﬀ ectiveness 
analysis in adults with tuberculosis21 indicate that 
replacement of smear microscopy with Xpert MTB/RIF 
is highly cost eﬀ ective.21 Our study adds to the body of 
evidence that lends support to WHO recommendations 
that Xpert MTB/RIF replace smear as the initial 
diagnostic test in suspected HIV-associated tuberculosis 
or multidrug-resistant tuberculosis, and as a follow-on 
test in settings where these types of tuberculosis are less 
of a concern.22 However, unlike the adult recom-
mendations for a single Xpert MTB/RIF on one sputum 
sample, these results indicate the need for repeated 
specimens in children. A repeat visit to collect a second 
specimen was needed in slightly more than half of 
children. Such repeat visits would have a negative 
implication on patient and clinic resources. However, 
two visits are the standard of care for children with 
suspected pulmonary tuberculosis because interpretation 
of skin test results needs a second visit within 48–72 h of 
placement. A second induced sputum specimen or 
nasopharyngeal aspirate could therefore be timed to 
coincide with this visit. 
Limitations of this study include the small number of 
HIV-infected children. Nevertheless, pulmonary 
tuberculosis was prevalent in HIV-infected children, 
with 16% having culture-conﬁ rmed disease and more 
than 60% having a clinical diagnosis. Moreover, this 
clinic is a typical primary care facility situated in a low-
income area of South Africa. A further limitation is the 
absence of on-site testing for Xpert MTB/RIF, which was 
not done as a point-of-care test. Operational challenges in 
scaling-up use of Xpert MTB/RIF and in establishing it 
as a point-of-care test might limit its usefulness.
This study also draws attention to the limitations of 
the available methods for conﬁ rmation of pulmonary 
tuberculosis in children, especially in primary care 
settings. Only 17% of children treated for pulmonary 
tuberculosis were culture-positive, showing the 
limitations of using culture conﬁ rmation as the 
reference standard for diagnosis. Cases in which 
children tested Xpert MTB/RIF-positive but culture-
negative were probably true cases of pulmonary 
tuberculosis, because all the children responded to 
tuberculosis treatment. However, only a few children 
(4% of the study population) were in this group. 
Therefore, better diagnostic tests are needed to reliably 
diagnose children with pulmonary tuberculosis. The 
assessment of new diagnostics in children is, however, 
challenging in view of the low sensitivity of culture as 
the reference standard. 
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